A Review on Application of Quality by Design (QbD) Principles to the Development of Age-Appropriate Pediatric Ondansetron Formulations

Author(s)	Mr Dhananjay Narendra Musale, Prof. Dr. Vijay Bhausaheb Jadhav
Country	India
Abstract	Ondansetron, a foundational 5-HT3 receptor antagonist, plays a crucial role in managing chemotherapy-induced, post-operative, and acute gastroenteritis-related vomiting in children. Despite its widespread use, significant challenges persist, notably the absence of established safety and efficacy data for children younger than four years. Furthermore, marked age-dependent pharmacokinetic (PK) variability, characterized by reduced drug clearance in neonates, mandates flexible, weight-based dosing to prevent overexposure. This review applies the Quality by Design (QbD) framework (ICH Q8(R2)) to develop age-appropriate ondansetron formulations (ODF or oral solution), establishing the Quality Target Product Profile (QTPP), Critical Quality Attributes (CQAs), and Control Strategy (ICH Q10). Through proactive Quality Risk Management (QRM) and Failure Mode and Effects Analysis (FMEA), it ensures the product’s safety, efficacy, and lifecycle quality control.
Keywords	Ondansetron, Pediatric Dosing, Quality by Design (QbD), QTPP, CQAs, CPPs, FMEA, Orodispersible Film (ODF), ICH Q8/Q9/Q10.
Field	Medical / Pharmacy
Published In	Volume 7, Issue 5, September-October 2025
Published On	2025-10-12
DOI	https://doi.org/10.36948/ijfmr.2025.v07i05.57670

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijfmr.com

International Journal For Multidisciplinary Research